KGbio
Vonny Willianti has a strong background in pharmaceuticals and biotechnology, with experience in business development and licensing. Vonny has worked in various roles in companies like PT Kalbe Genexine Biologics and PT Kalbe Farma, Tbk. Vonny is known for being honest, energetic, and passionate about problem-solving. Vonny's education includes a degree in pharmaceutical science and technology from Institut Teknologi Bandung.
KGbio
KGbio is a clinical-stage biotechnology company focused on bringing biologics medical innovation to markets outside the US/Canada, Western Europe and China. The business model revolves around in-licensing novel biologics and select biosimilars in oncology and high-specialty therapeutic areas (typically pre-IND or early clinical stage), with the objective to out-license them in target geographies after finishing clinical development as well as regulatory and reimbursement approvals. Platforms of interest currently include Fc-fusion proteins, antibodies, bispecifics, ADCs, cell therapies and therapeutic vaccines. The company is backed by Asian pharma companies Kalbe (market cap US$5.5 billion) and Genexine (market cap US$1.3 billion) and US private equity giant General Atlantic (AUM US$ 78 billion).